NFKB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL59495	0.59	4/20
SCHEMBL12261	0.55	4/20
SCHEMBL60513	0.52	4/20
SCHEMBL36172	0.47	4/20
SCHEMBL9394	0.42	4/20
Biochanin (SCHEMBL61258)	1.00	3/20
Prunetin (SCHEMBL73420)	0.90	3/20
SCHEMBL52223	0.76	3/20
SCHEMBL52224	0.76	3/20
Pratensein (SCHEMBL73557)	0.73	3/20
SCHEMBL59673	0.73	3/20
SCHEMBL60050	0.72	3/20
Ataluren (SCHEMBL60614)	0.69	3/20
Ataluren (SCHEMBL59165)	0.68	3/20
Ataluren (SCHEMBL59167)	0.68	3/20
SCHEMBL23715	0.63	3/20
Ataluren (SCHEMBL59166)	0.62	3/20
SCHEMBL60044	0.56	3/20
SCHEMBL33121	0.54	3/20
SCHEMBL60632	0.51	3/20

Clinical trials — most relevant to NFKB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Lepidium Sativum Extract Versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy	PHASE4	COMPLETED
Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus	PHASE2/PHASE3	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk	PHASE2/PHASE3	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	PHASE1/PHASE2	COMPLETED
Sodium Bicarbonate in Cardiac Surgery	PHASE2	COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study	PHASE2	COMPLETED
Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot	PHASE2	COMPLETED
Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy	PHASE2	COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	PHASE2	COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation	PHASE2	ACTIVE_NOT_RECRUITING
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE1	COMPLETED
Diagnosis of Inflammatory Bowel Disease	nan	NOT_YET_RECRUITING
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients	nan	COMPLETED
Mechanisms of Insulin Resistance in Humans	nan	COMPLETED
Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia	nan	COMPLETED
Magnesium and Vitamin D Combination for Post-COVID Syndrome	nan	COMPLETED
Post-surgery Systemic Inflammation and Neuro-immune Interactions	nan	COMPLETED
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals	nan	UNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NFKB2 binder may also engage these)

Protein	Name	Similarity
Q9WTK5	—	1.000	Q9WTK5 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.996	landscape →
P98150	—	0.996	P98150 →
P25799	—	0.996	P25799 →
Q6F3J0	—	0.990	Q6F3J0 →
NR1H2	Oxysterols receptor LXR-beta	0.990	landscape →
D3ZEY4	—	0.989	D3ZEY4 →
O75064	—	0.989	O75064 →
Q63618	—	0.988	Q63618 →
Q63369	—	0.988	Q63369 →
Q95L87	—	0.988	Q95L87 →
GAK	Cyclin-G-associated kinase	0.988	landscape →
NR5A1	Steroidogenic factor 1	0.988	landscape →
JAK3	Tyrosine-protein kinase JAK3	0.987	landscape →
KDM1A	Lysine-specific histone demethylase 1A	0.987	landscape →
Q6P5E8	—	0.987	Q6P5E8 →
Q3U1Y4	—	0.987	Q3U1Y4 →
O35071	—	0.986	O35071 →
P10360	—	0.986	P10360 →
P97874	—	0.986	P97874 →
Q8K1S3	—	0.986	Q8K1S3 →
Q8K2H4	—	0.986	Q8K2H4 →
O08674	—	0.986	O08674 →
Q9Y4C4	—	0.986	Q9Y4C4 →
Q04861	—	0.986	Q04861 →
Q99KY4	—	0.986	Q99KY4 →
P50569	—	0.986	P50569 →
P33242	—	0.986	P33242 →
Q2HJE1	—	0.986	Q2HJE1 →
Q9GKL2	—	0.986	Q9GKL2 →